Rigel Pharmaceuticals (RIGL)

$39.12 +1.16 (3.06%)
Market Cap 689.01M
Revenue (ttm) 179.28M
Net Income (ttm) 17.49M
EPS (ttm) N/A
PE Ratio 6.48
Forward PE 9.30
Profit Margin 9.76%
Debt to Equity Ratio 0.25
Volume 368,000
Avg Vol 658,326
Day's Range N/A - N/A
Shares Out 18.15M
Stochastic %K 18%
Beta 1.11
Analysts Strong Sell
Price Target $51.20

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a suscept...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 1100
Fax: 650 624 1101
Address:
611 Gateway Boulevard, Suite 900, South San Francisco, United States
Namhguab
Namhguab Jan. 15 at 2:44 AM
$RIGL Raul is about 65 years ok so those options he got thru the years automatically vest upon retiring. Does anyone honestly think the man is gonna roll the dice until 2030 on not kicking this over the goal line to literally double his net worth? I call bs on it. This stuff he pulled today by sweeping a lot of stuff under the rug and acting like this company will be under his leadership until he’s 70 is complete garbage. Couple that with zero insider buys or sells and you can complain about the buyout talks all you want; but it is a legitimate reality why all this is happening.
1 · Reply
MaxKlim
MaxKlim Jan. 15 at 1:43 AM
$RIGL https://www.marketbeat.com/instant-alerts/rigel-pharmaceuticals-inc-nasdaqrigl-given-consensus-rating-of-moderate-buy-by-analysts-2026-01-13/
0 · Reply
DBales26
DBales26 Jan. 14 at 11:51 PM
$RIGL Yes a BO is likely even more now. This presentation sounded like a man scrambling and speaking horribly because he realizes he will be out of a job soon. He's speaking in such long term and superlative situations, where I'm sure other shareholders are trying to understand what the heck is going on. It's not a safe standalone company given Raul's track record and past clinical trial performance so these assets should be in the hands of a large pharma. Notice he didn't talk about Lilly or RIPK1. It's in their investor presentation on Rigel's website so why skip it at JP? Are you hiding something Raul? This could all be over very soon.
1 · Reply
tobeme100
tobeme100 Jan. 14 at 11:43 PM
$RIGL Ok Lady and gentlemen. Do you guys still think a BO possible after this or in near term?
1 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:40 PM
$RIGL Strategic Insights and Future Outlook ​Early Intervention: The company emphasizes that earlier treatment with their products yields better results. For instance, the response rate is 94% in second-line treatment, compared to 50% in fifth-line treatment. ​Impact of the Inflation Reduction Act (IRA): This US legislation helped eliminate the "donut hole" (coverage gap). This resulted in a drastic reduction in patients discontinuing treatment due to costs during the first quarter. ​Future Growth (2030 and beyond): High expectations are placed on the IRAK1/4 inhibitor program (R289), currently in development for lower-risk MDS (Myelodysplastic Syndrome). The company views this as a "multi-hundred million or billion-dollar" opportunity.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:27 PM
$RIGL Future (2030 and beyond): The company has high expectations for its IRAK1/4 inhibitor program, which is currently in development for indications such as low-risk MDS (Myelodysplastic Syndrome). This is viewed as a multi-hundred million or even billion-dollar opportunity.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:26 PM
$RIGL strategic Insights and Market Developments ​Line of Treatment: The company emphasizes that earlier treatment with their products yields better results. For example, the response rate is 94% in second-line treatment, compared to 50% in fifth-line treatment. ​Inflation Reduction Act (IRA): This US legislation helped close the "donut hole" (a gap in medication coverage). As a result, the number of patients dropping out of treatment in Q1 due to affordability issues has drastically decreased. ​Future (2030 and beyond): The company has high expectations for its IRAK1/4 inhibitor program, which is currently in development for indications such as low-risk MDS (Myelodysplastic Syndrome). This is viewed as a multi-hundred million or even billion-dollar opportunity.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:26 PM
$RIGL Gavreto (Pralsetinib - referred to as "Gabra2" in transcript): ​Acquired in 2024. At the time of acquisition, sales were $7 million per quarter; this has since grown to over $10 million per quarter. ​Rezlidhia (Olutasidenib - licensed from Forma Therapeutics): ​In-licensed in 2022 for the treatment of relapsed/refractory IDH1-positive AML (Acute Myeloid Leukemia). ​Approved and launched ahead of schedule, with sales now reaching nearly $10 million per quarter.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:25 PM
$RIGL Financial Performance and Growth ​Stellar 2025: The year 2025 is described as a "top year" with substantial growth in commercial activities. Revenue increased by nearly $90 million. ​Quarterly Records: Every quarter was a record-breaking quarter for that period. In Q4 2025, there was a growth of 41% compared to the same quarter the previous year. ​Historical Growth: The company reports 35% growth from 2002–2022 and anticipates a new "inflection point" in the next five years.
0 · Reply
ultistock
ultistock Jan. 14 at 11:19 PM
$RIGL No mention of Lilly and the RIPK1 program. Does anyone know when the results of the phase 2 study in rheumatoid arthritis will be announced?
1 · Reply
Latest News on RIGL
Rigel Provides Business Update and 2026 Outlook

Jan 12, 2026, 8:05 AM EST - 2 days ago

Rigel Provides Business Update and 2026 Outlook

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jan 9, 2026, 8:05 AM EST - 5 days ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:05 AM EST - 7 days ago

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rigel Pharma: Formulating A Game Plan For 2026

Jan 1, 2026, 4:41 AM EST - 13 days ago

Rigel Pharma: Formulating A Game Plan For 2026

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Dec 7, 2025, 9:30 AM EST - 5 weeks ago

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Rigel Pharma: Q3 Earnings Showcase Robust Growth

Nov 26, 2025, 8:15 AM EST - 7 weeks ago

Rigel Pharma: Q3 Earnings Showcase Robust Growth

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:05 AM EST - 7 weeks ago

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Nov 17, 2025, 8:05 AM EST - 2 months ago

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Rigel to Present at the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 8:05 AM EST - 2 months ago

Rigel to Present at the Jefferies Global Healthcare Conference in London

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:06 PM EST - 2 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:01 PM EST - 2 months ago

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

Nov 3, 2025, 9:05 AM EST - 2 months ago

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Oct 30, 2025, 2:20 PM EDT - 2 months ago

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Oct 29, 2025, 8:05 AM EDT - 2 months ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

Oct 8, 2025, 8:05 AM EDT - 3 months ago

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion

Sep 25, 2025, 10:53 PM EDT - 3 months ago

Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion

Rigel to Participate in Upcoming September Investor Conferences

Aug 26, 2025, 8:05 AM EDT - 5 months ago

Rigel to Participate in Upcoming September Investor Conferences

Overlooked Stock: RIGL Nearly Doubles Stock in August

Aug 15, 2025, 5:20 PM EDT - 5 months ago

Overlooked Stock: RIGL Nearly Doubles Stock in August

The Big 3: OPEN, RIGL, JOBY

Aug 15, 2025, 12:00 PM EDT - 5 months ago

The Big 3: OPEN, RIGL, JOBY

JOBY OPEN

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

Aug 13, 2025, 11:58 PM EDT - 5 months ago

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:02 PM EDT - 5 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Jul 29, 2025, 8:05 AM EDT - 6 months ago

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Rigel to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:05 AM EDT - 8 months ago

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 22, 2025, 5:20 PM EDT - 8 months ago

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 7, 2025, 6:16 PM EDT - 9 months ago

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:13 PM EDT - 9 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:01 PM EDT - 9 months ago

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Apr 29, 2025, 8:05 AM EDT - 9 months ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Apr 4, 2025, 3:31 PM EDT - 10 months ago

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Mar 27, 2025, 8:05 AM EDT - 10 months ago

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Appoints Mark W. Frohlich, M.D.

Mar 10, 2025, 8:05 AM EDT - 11 months ago

Rigel Appoints Mark W. Frohlich, M.D.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:29 PM EST - 11 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 4:01 PM EST - 11 months ago

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 25, 2025, 8:05 AM EST - 11 months ago

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Jan 22, 2025, 8:05 AM EST - 1 year ago

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel Provides Business Update and 2025 Outlook

Jan 13, 2025, 8:05 AM EST - 1 year ago

Rigel Provides Business Update and 2025 Outlook

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Jan 9, 2025, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:05 AM EST - 1 year ago

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Dec 30, 2024, 8:30 AM EST - 1 year ago

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Dec 9, 2024, 12:02 PM EST - 1 year ago

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Dec 2, 2024, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 8:05 AM EST - 1 year ago

Rigel to Present at the Jefferies London Healthcare Conference

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:25 PM EST - 1 year ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:01 PM EST - 1 year ago

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 1 year ago

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Oct 24, 2024, 4:35 PM EDT - 1 year ago

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Oct 16, 2024, 10:00 AM EDT - 1 year ago

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Rigel Pharmaceuticals: Looking For More Growth

Oct 10, 2024, 7:32 AM EDT - 1 year ago

Rigel Pharmaceuticals: Looking For More Growth

Namhguab
Namhguab Jan. 15 at 2:44 AM
$RIGL Raul is about 65 years ok so those options he got thru the years automatically vest upon retiring. Does anyone honestly think the man is gonna roll the dice until 2030 on not kicking this over the goal line to literally double his net worth? I call bs on it. This stuff he pulled today by sweeping a lot of stuff under the rug and acting like this company will be under his leadership until he’s 70 is complete garbage. Couple that with zero insider buys or sells and you can complain about the buyout talks all you want; but it is a legitimate reality why all this is happening.
1 · Reply
MaxKlim
MaxKlim Jan. 15 at 1:43 AM
$RIGL https://www.marketbeat.com/instant-alerts/rigel-pharmaceuticals-inc-nasdaqrigl-given-consensus-rating-of-moderate-buy-by-analysts-2026-01-13/
0 · Reply
DBales26
DBales26 Jan. 14 at 11:51 PM
$RIGL Yes a BO is likely even more now. This presentation sounded like a man scrambling and speaking horribly because he realizes he will be out of a job soon. He's speaking in such long term and superlative situations, where I'm sure other shareholders are trying to understand what the heck is going on. It's not a safe standalone company given Raul's track record and past clinical trial performance so these assets should be in the hands of a large pharma. Notice he didn't talk about Lilly or RIPK1. It's in their investor presentation on Rigel's website so why skip it at JP? Are you hiding something Raul? This could all be over very soon.
1 · Reply
tobeme100
tobeme100 Jan. 14 at 11:43 PM
$RIGL Ok Lady and gentlemen. Do you guys still think a BO possible after this or in near term?
1 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:40 PM
$RIGL Strategic Insights and Future Outlook ​Early Intervention: The company emphasizes that earlier treatment with their products yields better results. For instance, the response rate is 94% in second-line treatment, compared to 50% in fifth-line treatment. ​Impact of the Inflation Reduction Act (IRA): This US legislation helped eliminate the "donut hole" (coverage gap). This resulted in a drastic reduction in patients discontinuing treatment due to costs during the first quarter. ​Future Growth (2030 and beyond): High expectations are placed on the IRAK1/4 inhibitor program (R289), currently in development for lower-risk MDS (Myelodysplastic Syndrome). The company views this as a "multi-hundred million or billion-dollar" opportunity.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:27 PM
$RIGL Future (2030 and beyond): The company has high expectations for its IRAK1/4 inhibitor program, which is currently in development for indications such as low-risk MDS (Myelodysplastic Syndrome). This is viewed as a multi-hundred million or even billion-dollar opportunity.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:26 PM
$RIGL strategic Insights and Market Developments ​Line of Treatment: The company emphasizes that earlier treatment with their products yields better results. For example, the response rate is 94% in second-line treatment, compared to 50% in fifth-line treatment. ​Inflation Reduction Act (IRA): This US legislation helped close the "donut hole" (a gap in medication coverage). As a result, the number of patients dropping out of treatment in Q1 due to affordability issues has drastically decreased. ​Future (2030 and beyond): The company has high expectations for its IRAK1/4 inhibitor program, which is currently in development for indications such as low-risk MDS (Myelodysplastic Syndrome). This is viewed as a multi-hundred million or even billion-dollar opportunity.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:26 PM
$RIGL Gavreto (Pralsetinib - referred to as "Gabra2" in transcript): ​Acquired in 2024. At the time of acquisition, sales were $7 million per quarter; this has since grown to over $10 million per quarter. ​Rezlidhia (Olutasidenib - licensed from Forma Therapeutics): ​In-licensed in 2022 for the treatment of relapsed/refractory IDH1-positive AML (Acute Myeloid Leukemia). ​Approved and launched ahead of schedule, with sales now reaching nearly $10 million per quarter.
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:25 PM
$RIGL Financial Performance and Growth ​Stellar 2025: The year 2025 is described as a "top year" with substantial growth in commercial activities. Revenue increased by nearly $90 million. ​Quarterly Records: Every quarter was a record-breaking quarter for that period. In Q4 2025, there was a growth of 41% compared to the same quarter the previous year. ​Historical Growth: The company reports 35% growth from 2002–2022 and anticipates a new "inflection point" in the next five years.
0 · Reply
ultistock
ultistock Jan. 14 at 11:19 PM
$RIGL No mention of Lilly and the RIPK1 program. Does anyone know when the results of the phase 2 study in rheumatoid arthritis will be announced?
1 · Reply
GO_DAWGS
GO_DAWGS Jan. 14 at 11:09 PM
$RIGL good recommendation on UAMY … making good money already. Thanks.
1 · Reply
Bsbl
Bsbl Jan. 14 at 11:07 PM
$RIGL not liking Raul talking about 2030.
1 · Reply
B4I4QQTRU18
B4I4QQTRU18 Jan. 14 at 4:48 PM
$RIGL oh my. I think next report may hold an update to quarterly institutional ownership.
0 · Reply
tobeme100
tobeme100 Jan. 14 at 3:26 PM
$RIGL 911 calling
1 · Reply
B4I4QQTRU18
B4I4QQTRU18 Jan. 14 at 1:56 PM
$RIGL upgrades And more should come. Joe at HC was a huge bull, but has fell silent. WTFU Joe. Looking for standard 10 am est attack to add more.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 1:36 PM
Enter: $RIGL Calls Strike Price: $38 Expiry Date: FEB 20 2026 Buy in Price: $4.96 - $5.50 Sell Price: $11.06 Profit : +123% (Turn every $1 into $2.23) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
nirok
nirok Jan. 14 at 1:33 PM
$RIGL Rigel Pharmaceuticals price target raised to $71 from $69 at Citi TheFly TheFly Jan 14, 2026, 05:45 AM A+ A- Citi raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $71 from $69 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect its better than expected Q4 revenue figures.
0 · Reply
silent_entry
silent_entry Jan. 14 at 12:57 PM
$RIGL $INFY Clinical meets IT services
0 · Reply
Gabriel1234
Gabriel1234 Jan. 14 at 11:19 AM
$RIGL https://www.tipranks.com/news/the-fly/rigel-pharmaceuticals-price-target-raised-to-71-from-69-at-citi-thefly?mod=mw_quote_news
1 · Reply
DosGatos
DosGatos Jan. 14 at 1:57 AM
$RIGL Starting to think Gabe is an AI bot sent from Raul
3 · Reply
Gabriel1234
Gabriel1234 Jan. 13 at 11:06 PM
$RIGL Key Takeaways: J.P. Morgan Conference: Rigel's CEO presented at the 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026, boosting visibility. Analyst Consensus: General consensus is positive ("Buy" or "Moderate Buy"), with strong upside potential and favorable metrics. Growth & Value: Analysts point to strong revenue forecasts, positive cash flow, and attractive valuation metrics (P/E, P/S). Clinical Progress: Promising Phase 1b data for R289 in myelodysplastic syndromes (MDS) is a key driver.
2 · Reply
GO_DAWGS
GO_DAWGS Jan. 13 at 9:20 PM
$RIGL Don’t sleep on the ARDS trial! 🙏 SYK and Bacterial Sepsis “The "SYK" Connection: Research indicates that SYK gene expression significantly increases in patients during septic shock. It acts as a key signaling molecule that can trigger an overactive immune response. Neutrophil Hyperactivation: During sepsis, immune cells called neutrophils can become hyperactive, leading to organ damage. High levels of SYK in these cells have been linked to acute kidney injury and other organ dysfunctions. Potential Treatments: Scientists are investigating SYK inhibitors (like fostamatinib, which is already FDA-approved for other conditions) as a way to "calm down" this overactive immune response without stopping the body's ability to fight bacteria.”
0 · Reply